STK25

Across TCGA pan-cancer cohorts, STK25 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated STK25 data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher STK25 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated STK25 expression acts as an unfavorable survival marker.

BLCA, SKCM, and HNSC are the cancer types where STK25 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	III,IV	0.132	0.684	<.001	18	view →
SKCM	DFS	Median	All	0.087	0.757	<.001	18	view →
HNSC	OS	Median	All	0.139	0.685	.003	12	view →
LGG	DFS	Median	All	0.147	0.829	<.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

STK25–BLCA (OS)

Open the BLCA breakdown →